Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation

Int J Mol Sci. 2018 Aug 23;19(9):2493. doi: 10.3390/ijms19092493.

Abstract

Recent studies have demonstrated that exosomal microRNAs (miRNAs) have the potential of facilitating molecular diagnosis. Currently, little is known about the underlying mechanism behind late-onset acute graft-versus-host disease (LA GVHD). Identifying differentially expressed miRNAs in exosomes should be useful for understanding the role of miRNAs in this disease. This study was established to investigate the relevance of miRNAs in exosomes derived from patients developing LA GVHD after allogeneic hematopoietic stem cell transplantation (HSCT). Plasma samples were collected from patients with LA GVHD (n = 5), non-GVHD (n = 5), and controls (n = 8) for exosomal miRNA expression profiling using a TaqMan low-density array; the results were validated by quantitative reverse transcription polymerase chain reaction (RT-PCR). We analyzed exosomal miRNAs differentially expressed among these three groups. MirTarBase was employed to predict potential target genes of the miRNAs specific for LA GVHD. We detected 55 miRNAs that were differentially expressed with a significant change >2.0-fold between LA GVHD and non-GVHD. Of these, we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression. Using quantitative RT-PCR, we further identified that miR-128 was significantly upregulated at the onset of LA GVHD compared with that in normal controls and is a promising diagnostic marker of LA GVHD, with an area under the curve (AUC) value of 0.975. MirTarBase analysis revealed that the predicted target genes of miR-128 are involved in the immune system and inflammation. Increased expression of miR-128 may serve as a novel, noninvasive biomarker for early LA GVHD diagnosis.

Keywords: exosomal miRNA; hematopoietic stem cell transplantation; late-onset acute graft-versus-host disease.

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Area Under Curve
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / genetics*
  • Calcineurin Inhibitors / therapeutic use
  • Case-Control Studies
  • Cyclosporine / therapeutic use
  • Exosomes / chemistry*
  • Exosomes / immunology
  • Female
  • Gene Expression Profiling
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / genetics*
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / mortality
  • Hematologic Neoplasms / genetics*
  • Hematologic Neoplasms / immunology
  • Hematologic Neoplasms / mortality
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Male
  • Methotrexate / therapeutic use
  • MicroRNAs / blood
  • MicroRNAs / genetics*
  • Middle Aged
  • Myeloablative Agonists / therapeutic use
  • ROC Curve
  • Survival Analysis
  • Tacrolimus / therapeutic use
  • Transplantation, Homologous

Substances

  • Biomarkers, Tumor
  • Calcineurin Inhibitors
  • MIRN128 microRNA, human
  • MicroRNAs
  • Myeloablative Agonists
  • Cyclosporine
  • Tacrolimus
  • Methotrexate